Cyclic AMP enhancing drugs modulate eicosanoid release from human alveolar macrophages
Related Experiment Videos
F D Beusenberg1, H C Hoogsteden, I L Bonta
1Department of Pharmacology, Faculty of Medicine, Erasmus University Rotterdam, The Netherlands.
Abstract:
The effect of the phosphodiesterase inhibitor isobutyl-methylxanthine (IBMX), salbutamol and sodium nitroprusside was evaluated regarding PGE2 and LTB4 release and cAMP and cGMP level in human alveolar macrophages obtained from controls and COPD patients. Basal levels per five million control- respectively COPD alveolar macrophages: cAMP 1.2 and 1.0 pmole; cGMP 8.4 and 9.1 fmole; PGE2 120 and 63 pg and LTB4 19.2 and 14.8 pg. In both populations IBMX increased cAMP level by 55-93% and salbutamol+IBMX by 285-252%. Except for the 61% rise in LTB4 release by salbutamol+IBMX the drugs hardly affected PGE2 and LTB4 release from control macrophages. In COPD alveolar macrophages, however, IBMX and IBMX+salbutamol largely reduced PGE2 release (63 vs 11 pg per 10(6) cells) but less efficiently increased LTB4. In both macrophage populations sodium nitroprusside (SNP) substantially increased (3-4 fold) cGMP level but did not affect eicosanoid production. Present results indicate that drugs which enhance cAMP level decrease PGE2 release from COPD macrophages and stimulate the release of LTB4 a chemotactic mediator involved in bronchial inflammatory reactions.
Insights
Drugs that increase cAMP levels reduce PGE2 release in COPD macrophages and stimulate LTB4 release, a key mediator in airway inflammation.
Area of Science:
- Immunology
- Pharmacology
- Respiratory Medicine
Background:
- Alveolar macrophages play a crucial role in COPD pathogenesis.
- Prostaglandin E2 (PGE2) and Leukotriene B4 (LTB4) are key inflammatory mediators.
- Cyclic AMP (cAMP) and cyclic GMP (cGMP) signaling pathways are involved in macrophage function.
Purpose of the Study:
- To investigate the effects of phosphodiesterase inhibitors and bronchodilators on mediator release from human alveolar macrophages.
- To compare the responses in macrophages from healthy controls and COPD patients.
- To elucidate the role of cAMP and cGMP in regulating inflammatory mediator production.
Main Methods:
- Human alveolar macrophages were isolated from controls and COPD patients.
- Cells were treated with isobutyl-methylxanthine (IBMX), salbutamol, and sodium nitroprusside (SNP).
- Levels of cAMP, cGMP, PGE2, and LTB4 were measured.
Main Results:
- IBMX and salbutamol significantly increased cAMP levels in both groups.
- In COPD macrophages, IBMX and salbutamol markedly reduced PGE2 release.
- SNP increased cGMP levels but did not affect eicosanoid production.
Conclusions:
- Drugs enhancing cAMP levels decrease PGE2 release from COPD macrophages.
- These drugs also stimulate LTB4 release, a chemotactic mediator in airway inflammation.
- Modulating cAMP levels represents a potential therapeutic strategy for COPD.